Dr. Joseph Kozikowski will present on the use of nanoscale molecular imaging in translational medicine at Merck research headquarters.
FRAMINGHAM, MA – August 30, 2006 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. will present to research and executive leadership at Merck Research Headquarters in West Point, PA.
As an authority on the development and commercialization of advanced medical technology, Dr. Kozikowski will share his perspectives in a presentation entitled “Optimizing Development: Translational Validation of Breast Cancer Targets” on September 20, 2006.
The presentation will address Dr. Kozikowski’s translational research in nanoscale molecular imaging and cancer as Chief Medical Officer and Study Medical Director of ART Advanced Research Technologies Inc. (Technoparc Saint-Laurent, CAN).
Quotes & Commentary:
“It is an honor to have been invited to present, and I thank the Merck executive leadership for their efforts in arranging this opportunity for learning,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.